Clinical decision-support only. For use by licensed dental professionals. Not a substitute for professional judgment or a complete drug reference. Always verify with primary sources.
← Back to search
Medication

Sitagliptin

Antihyperglycemic (DPP-4 inhibitor)

Brand names: Januvia

Oral health effects

  • Indirect periodontal/caries risk via glycemic control

    These agents do not act directly on the mouth, but the underlying diabetes (and how well it is controlled) strongly influences periodontal disease, healing, and infection risk.

    Clinical management: Reinforce that good glycemic control supports periodontal health; coordinate care and note HbA1c.

  • Lip/tongue/facial swelling (angioedema)

    Postmarketing reports of serious hypersensitivity reactions including angioedema, usually within the first 3 months of therapy (label Warnings).

    Clinical management: Ask about any lip, tongue or facial swelling since starting the drug; acute swelling of the lips, tongue or throat in the chair is a medical emergency — activate the emergency protocol and refer the patient back to the prescriber.

  • Mouth ulcers / stomatitis

    Mouth ulceration and stomatitis are listed among postmarketing adverse reactions (frequency not established).

    Clinical management: Consider the drug as a possible cause of new, unexplained oral ulceration after starting sitagliptin; provide symptomatic care (bland rinses, topical anesthetic) and inform the prescriber if persistent.

Sources

  1. Adverse drug events in the oral cavity. Yuan A, Woo SB. Oral surgery, oral medicine, oral pathology and oral radiology, 2015.
  2. Sitagliptin prescribing information (FDA label) Teva Pharmaceuticals, Inc. / DailyMed, 2025.
  3. A review and guide to drug-associated oral adverse effects-Oral mucosal and lichenoid reactions. Part 2. Teoh L, Moses G, McCullough MJ. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2019.